Form 4: Pfizer Director James Quincey Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Director James Quincey reports acquiring phantom stock units representing deferred director's compensation in Pfizer Inc.
Summary
- On September 30, 2024, James Quincey, a director of Pfizer Inc., acquired 1,338.977 phantom stock units.
- These units represent deferred director's compensation, including dividend equivalents.
- The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
- The price of the transaction was $28.94 per unit.
- Following the transaction, Quincey directly owns 52,710.584 shares of Pfizer common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding director compensation, indicating a neutral sentiment.
Future Outlook
The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
Industry Context
This filing is a routine disclosure of a director's compensation in the form of phantom stock units, which is a common practice in corporate governance.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it relates to director compensation.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of transaction: Acquisition of phantom stock units. |
| 10/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.